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Abstract
Perturbed mitochondrial bioenergetics constitute a core
pillar of cancer-associated metabolic dysfunction. While
mitochondrial dysfunction in cancer may result
from myriad biochemical causes, a historically neglected
source is that of the mitochondrial genome. Recent
large-scale sequencing efforts and clinical studies have
highlighted the prevalence of mutations in
mitochondrial DNA (mtDNA) in human tumours and
their potential roles in cancer progression. In this review
we discuss the biology of the mitochondrial genome,
sources of mtDNA mutations, and experimental evidence
of a role for mtDNA mutations in cancer. We also
propose a ‘metabolic licensing’ model for mtDNA
mutation-derived dysfunction in cancer initiation and
progression.
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Mitochondria and metabolism
The mammalian mitochondrion, though primarily of pro-
teobacterial origin, is an evolutionary mosaic composed of
elements drawn from and recombined between eukarya,
archaea, bacteria, and phage [1–3]. Throughout evolution
most mitochondrial genetic information has transferred to
the nucleus; however, mitochondria have retained a ves-
tigial genome, mitochondrial DNA (mtDNA), allowing a
form of genomic symbiosis through which mitochondria
maintain a degree of cellular control, communicating with
the nucleus through an incompletely understood series of
retrograde signals [4].
Mitochondria are essential organelles for eukaryotes,
performing key functions ranging from the generation of
bioenergetic intermediates such as ATP and GTP, to the
synthesis of nucleotides, Fe-S clusters, haem and amino
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acids, Fe2+/Ca2+ handling, inflammation, and apoptosis
[5]. By virtue of their position at such a cellular nexus,
dysfunction of mitochondria and subsequent metabolic
defects are implicated in diverse human pathologies, in-
cluding both sporadic and familial forms of cancer [6].
Perturbed cellular metabolism in cancerous tissue is
an historic and widely recognised phenomenon [7], with
recent seminal studies defining specific pathways to
mitochondrial dysfunction in cancer through mutation
or dysregulated expression of nuclear DNA encoding
mitochondrial proteins [8, 9]. More recently, a less-
discussed orthogonal route to mitochondrial dysfunction
in cancer has been considered: mutation and dysregula-
tion of the mitochondrial genome. In this article, we will
review the most recent evidence in support of a role for
mtDNA mutations in cancer, the likely source of these
mutations, and major challenges that remain to be ad-
dressed by the field.
Genetics of mammalian mitochondria
The mammalian mitochondrion is formed of ~ 1200
proteins, the vast majority of which are encoded in
and expressed from the nuclear genome, whilst a
small subset of these proteins is encoded by the
spatially and heritably separate mitochondrial genome
[10, 11] (Fig. 1a). The human mitochondrial genome
is a genetically compact, circular, double-stranded
DNA molecule of 16.5 kb, typically present at between
100 and 10,000 copies per cell on a cell type-specific
basis [12, 13]. In most higher metazoans, mtDNA is
firmly anchored to the inner mitochondrial membrane
(IMM) within the mitochondrial matrix, packaged
into protein–DNA complexes known as nucleoids,
which are formed principally of the mitochondrial
transcription factor A (TFAM) [14, 15]. Human
mtDNA encodes only 11 mRNAs, 22 tRNAs, and 2
rRNAs [16] (Fig. 1b). In total, 13 extremely hydro-
phobic polypeptides from these 11 mRNAs are co-
translationally inserted into the IMM, where they
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form core, membrane-bound subunits of respiratory
chain complexes I, III, IV, and ATP synthase.
Human mtDNA has an unremarkable GC content
(44.4%); however, the biased distribution of these
bases across the two strands results in variable buoy-
ancy when mtDNA is resolved using an alkaline cae-
sium chloride gradient, resulting in the G-rich ‘heavy
strand’ (H-strand) and C-rich ‘light strand’ (L-strand)
nomenclature [17]. An unusual feature of mtDNA is
the displacement loop (D-loop), a triple-stranded re-
gion of the molecule that incorporates a short single-
stranded DNA fragment known as 7S DNA (Fig. 1b).
The D-loop is believed to be the product of mtDNA
replication events that abort at the termination asso-
ciated sequence (TAS) within the major non-coding
region (NCR). The functional relevance of 7S DNA
and the D-loop remains to be fully elucidated (for a
thorough review see [18]).
Fig. 1. Genetic composition of human mitochondria. a Dual-genome origins of the mitochondrial electron transport chain (ETC). The ETC
comprises ~ 90 individual protein subunits, encoded by both nuclear (nDNA) and mitochondrial genomes (mtDNA). Assembly of a functional ETC
requires co-ordinated regulation and expression of these components by the two separate genomes. Beyond the 13 ETC proteins encoded in
mtDNA, the remainder of the human mitochondrial proteome is encoded in and expressed from the nuclear genome. Import of nuclear-
encoded proteins through membrane-embedded protein translocases into the mitochondrial matrix requires a membrane potential between the
intermembrane space (IMS) and the matrix (white circles). Nuclear encoded components coloured brown, mitochondria-encoded components in
blue, red, green, and yellow by complex. Complex III is shown as a dimer. b Annotated genetic features of human mtDNA. Eleven mRNAs (two
overlapping) encode 13 polypeptides forming essential components of the ETC. These are expressed using an altered genetic code, enabled by a
full complement of 22 mitochondria-specific tRNAs also encoded in mtDNA. Resulting proteins are co-translationally inserted into the inner
mitochondrial membrane (IMM) by mitochondrial ribosomes, which contain structural RNA components of exclusive mitochondrial origin (12S
rRNA, 16S rRNA, and mt-tRNAVal). An expanded view of the displacement loop (D-loop) and major non-coding region (NCR), incorporating 7S
DNA, with indication of key loci for mtDNA transcription (heavy strand promoter, HSP; light strand promoter, LSP), replication (origin of heavy
strand, OH) and other prominent elements relevant to these functions (conserved sequence block 1–3, CSB1–3; termination-associated sequence,
TAS). c Primary polycistronic maps of transcription of mtDNA from LSP and HSP. Near-complete genome length transcripts are produced through
transcription by the mitochondrial RNA polymerase (POLRMT) mitochondrial transcription elongation factor (TEFM) complex, which undergo
endonucleolytic processing to liberate individual gene products, and further modifications of mRNA, rRNA, and tRNA molecules to enable
efficient translation
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The mitochondrial genome is expressed through tran-
scription by a complex consisting of mitochondrial RNA
polymerase (POLRMT) and mitochondrial transcription
elongation factor (TEFM) [19] into near genome length
polycistrons from either the light-strand promoter (LSP)
or the heavy-strand promoter (HSP) (Fig. 1c). Most
mRNA-coding genes are separated, or punctuated, by
tRNA genes, which are excised from the primary tran-
script by ELAC2 and mitochondrial RNase P. These
molecules are then extensively processed (polyadenyla-
tion, various base and sugar modifications [20]), likely
within mitochondrial RNA granules, before translation
and co-translational insertion of the polypeptides into
the IMM by mitochondrial ribosomes [21].
The replication of mtDNA proceeds in an asynchron-
ous manner through a strand-displacement mechanism,
initiated by an RNA primer transcribed by POLRMT
from LSP that terminates at a G-quadruplex in nascent
RNA and non-template DNA formed at conserved se-
quence block 2 (CSB2) [22]. The replicative mitochon-
drial DNA polymerase γ (Pol γ) binds and initiates DNA
synthesis from this primer at the origin of the heavy
strand (OH) within the NCR, located on the L-strand
(Fig. 2). The advancing replication fork, consisting of the
phage-like Pol γ and helicase Twinkle, synthesises
daughter H-strand using L-strand DNA as the template,
with the displaced parental H-strand, once unwound by
Twinkle, being rapidly coated in mitochondrial single-
stranded binding protein (mtSSB) (Fig. 2). The replica-
tion fork proceeds and, after ~ 11 kb, the origin of the
light strand (OL) is revealed in the parent H-strand
DNA, forming a stem-loop structure that allows initi-
ation of L-strand synthesis from an RNA primer gener-
ated by POLRMT [23]. Once both strands have
completed the replicative cycle, RNA primers are re-
moved by RNA:DNA hybrid-specific ribonuclease RNase
H1 and Flap endonuclease 1 (FEN1), or FEN1-like activ-
ity, with gaps filled and ligated by Pol γ and DNA ligase
III, respectively [23]. An unusual, theta-like structure in
DNA is formed, with two complete mtDNA molecules
linked through a hemicatenated junction near the NCR.
Recent data shed light on the segregation of mtDNA fol-
lowing replication, with parent and daughter molecule
resolution occurring in a topoisomerase 3α-dependent
manner [24]. Some controversy exists concerning the
exact sequence of events in mtDNA replication, and par-
ticular disagreements on the role of RNA in mtDNA
replication, either in the form of Okazaki fragments or
Fig. 2. Replication of mtDNA by asynchronous strand-displacement synthesis. Initiation of replication occurs through synthesis of an RNA primer
from LSP that forms a G-quadruplex with non-template DNA and terminates at CSB2. The replicative mitochondrial DNA polymerase γ (Pol γ)
begins DNA synthesis from this primer around OH, with helicase Twinkle unwinding upstream DNA. The parental L-strand acts as the template for
synthesis, with the displaced H-strand being temporarily coated in mitochondrial single-stranded binding protein (mtSSB). Once Twinkle reveals
OL, a stem-loop forms in the ssDNA of the parental H-strand, allowing synthesis of a short RNA primer by POLRMT and subsequent synthesis of
the daughter L-strand using the displaced parental H-strand as a template. DNA synthesis proceeds until two complete, hemicatenated mtDNA
molecules are produced. RNA primers are removed in a two-nuclease pathway involving RNase H1 and flap endonuclease 1 (FEN1) or FEN1-like
activity (not shown), and hemicatenanes are resolved by mitochondrial topoisomerase 3α (Top3α)
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as nascent pre-mRNA molecules coating displaced
strands, have attracted attention historically [25]. How-
ever, the weight of evidence currently favours the classic,
asynchronous strand-displacement model [26].
Despite the long-since established status of mtDNA as
a multicopy genome with robust copy number control,
the basis of any mechanism regulating copy number re-
mains a poorly understood phenomenon [13]. The im-
portance of maintaining mtDNA copy number is also
unclear, with several striking examples of total or near-
total loss of mtDNA copy number in vitro and in vivo
resulting in subtle or temporally delayed effects on mito-
chondrial function [27, 28]. The multi-copy nature of
mtDNA allows for the existence of mixed populations of
mtDNA molecules, where not all genomes are identical,
a phenomenon known as heteroplasmy. In the disease
context, the extent of mtDNA mutation heteroplasmy
within a given cell or individual plays an important role
in the development of mitochondrial dysfunction, and
mitochondrial DNA heterogeneity is an important con-
cept, both in disease and non-disease states [29].
Source of mtDNA mutations in disease
As with any genetic material, mtDNA is susceptible to
damage, errors of nucleic acid metabolism, and imper-
fect replicative fidelity. Historically, a higher basal muta-
tion rate of mtDNA as compared to nuclear DNA [30]
combined with a broadly inferred lack of mtDNA repair
from early studies (see for instance [31]) have led to
much of the mtDNA mutational burden being ascribed
to oxidative damage, specifically from radical oxygen
generated by the respiratory chain, and ineffective or ab-
sent mtDNA repair mechanisms. That mutations of
mtDNA accumulate during ageing and are a common
feature of age-related diseases is suggested to further
support this view through a ‘vicious cycle’ theory, where
greater mutational burden begets a greater oxidative
stress, leading to more extensive mutagenesis [32]. Con-
sidering our current understanding, however, such a
view of mtDNA mutations appears implausible.
While mitochondria lack key nucleotide excision re-
pair (NER) proteins necessary to remove classic bulky
DNA adducts (e.g. pyrimidine dimers, cisplatin cross-
links), the existence of both short and long patch base
excision repair (BER) and single strand break repair
pathways within the mitochondrial compartment have
been confirmed [33]. However, mitochondria employ an
esoteric strategy for handling of double strand breaks,
rapid degradation of the entire genome by components
of the replisome [34, 35], that effectively rules out effi-
cient homologous recombination (HR), microhomology-
mediated end joining (MMEJ), and non-homologous end
joining (NHEJ) [36].
Recent data cast doubt specifically on the role of oxi-
dative stress in driving mtDNA mutation. The proximal
radical oxygen species generated by the respiratory
chain, superoxide (O2
•-), is not an efficient DNA modi-
fier [37–39]. However, in the presence of ferric iron,
O2
•- can, through Haber-Weiss and Fenton chemistry,
yield hydroxyl radicals (•OH) that readily react with,
among essentially any organic molecule, DNA bases
(Fig. 3a). An intriguing series of experiments with
mitochondria-specific murine knockouts of DNA repair
glycosylases OGG1 and MUTYH, necessary for excision
of the most common oxidised base derivative, 8-oxo-
guanine, demonstrate an unaltered mtDNA mutation
load when compared with controls [40]. Mitochondrial
superoxide dismutase (SOD2) catalyses the conversion
of O2
•- to hydrogen peroxide (H2O2), which is reactive
with nucleic acid [41] but readily diffuses out of mito-
chondria, unlike O2
•-. A further, compelling experiment
assessing crosses of OGG1 knockout mice with SOD2
knockout mice did not demonstrate enhanced mtDNA
mutation burden in either SOD2 mice alone or double
knockouts (Fig. 3b) [40]. Overall, these experiments indi-
cate that oxidative damage might not be a major source
of mtDNA mutations, as initially believed.
As oxidative damage to mtDNA appears not to pro-
vide an adequate explanation for observed mutagenesis,
an obvious next candidate would be replicative polymer-
ase error. However, the processive fidelity of Pol γ is
among the best of known polymerases from all domains
of life [42]. As such, the argument for polymerase error
in mtDNA mutagenesis, particularly in the absence of
oxidative damage-induced mutation, is difficult to recon-
cile with the enhanced rate of mutation acquisition ob-
served in mitochondria generally, beyond the cancer
context [30].
Interestingly, mtDNA mutations found in human can-
cers display a strand-asymmetric mutational signature.
Such an observation may indicate that the strand-
specific mode of mtDNA replication (Fig. 2), rather than
polymerase error itself, is a likely explanation of
mutagenesis.
mtDNA mutations in cancer
Anecdotal reports on the presence of mtDNA mutations
in excised tumours have featured in the cancer literature
for several decades (for detailed reviews see [9, 43, 44].
Yet, mitochondrial genetics in cancer has been largely
neglected, due in part to the attention paid to nuclear
DNA but also to technical issues that surrounded accur-
ate measurement of mtDNA mutations. For instance, it
was observed that many of the variants present in cancer
samples were related to mitochondrial haplogroups ra-
ther than genuine mutations and were, therefore, indica-
tive of sample contamination [45]. Further, it was
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proposed that detected DNA sequences presumed to be
mtDNA are instead nucleus-embedded mitochondrial
sequences (NUMTs), portions of mtDNA transferred to
the nuclear genome during evolution. The increased
chromosomal instability in tumours might lead to an
increase in NUMT abundance, which could be inadvert-
ently detected as true mtDNA mutations (discussed in
[46]). These experimental issues persisted until recently,
Fig. 3. The source and nature of mutations in mtDNA. a Simple schematic of radical oxygen generation by the mitochondrial ETC. Superoxide
(O2
•-), the proximal mitochondria radical oxygen species, is primarily produced at the flavin mononucleotide site of complex I, and the Qo site of
complex III. O2
•- is rapidly dismutated to hydrogen peroxide (H2O2) by mitochondrial superoxide dismutase (SOD2). H2O2 may act as a signalling
molecule, but can also introduce oxidative lesions to lipid, protein, and nucleic acid. In the presence of O2
•- and ferric iron, H2O2 may also participate in
redox cycling Fenton and Haber-Weiss chemistry, producing highly reactive hydroxyl radicals (•OH) that present a major oxidative stress to biological
systems. b Skeletal formula of deoxyguanosine (dG) and its oxidised derivative 8-oxo-guanosine, which can be produced through reaction with either
H2O2 or
•OH (phosphates not depicted for clarity). Theoretically, this oxidation should result in G > T mutations following erroneous DNA replication;
however, no increase in such mutations is detected in mtDNA following: knockout of individual DNA glycosylases required for repair of this lesion
(ΔMUTYH, ΔOGG1), increased oxidative burden (ΔSOD2), or even a double knockout (ΔOGG1, ΔSOD2) in mice [40]. c The nature of mtDNA mutations
detected in 527 human tumours of varying pathology. Regions and genes within mtDNA that are mutated with higher than expected occurrence and
recurrence are indicated in grey. The distribution of mutations is strand asymmetric, with significantly increased C > T burden (> 10 times expected
frequency) on the H-strand, and significantly increased T > C burden (~ 2.5 times expected frequency) on the L-strand. These differences are likely due
to differing replicative modes of the two strands (Fig. 2). Mutation distribution is for illustrative purposes only. Based on data from [29]
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when the availability of larger datasets, such as the Inter-
national Cancer Genome Consortium (ICGC) and the
Cancer Genome Atlas (TCGA), and better analytical ap-
proaches demonstrated that approximately 60% of all
solid tumours bear at least one mtDNA mutation [47–
49]. The vast majority of these mutations are C > T and
T > C transitions, present in strand asymmetric propor-
tion across the H and L strands, respectively (Fig. 3c),
likely due to the differing replicative modes of these
strands (Fig. 2), and do not fit mutational patterns asso-
ciated with oxidative damage (Fig. 3b) [48, 49]. Muta-
tions and heteroplasmies that would otherwise be
cleared through purifying selection occur throughout
the mitochondrial genome in these cancers, with notably
increased incidence in the NCR, ND5 and a broad re-
gion containing ND2, OL, and several tRNA genes (Fig.
3b). The nature of these mutations, whether profoundly
deleterious (nonsense and frameshift mutations) or less
severe (majority of missense mutations and mutations in
non-protein coding regions), is broadly consistent with
their prevalence and abundance; severe mutations are
less common and demonstrate a trend towards purifying
selection, whereas regulatory region variance is more
common and subject to positive selection [49]. A sub-
stantial proportion of mutations are at high levels of het-
eroplasmy (> 50% mutant load), with a minority (~ 8% of
tumours) achieving near-complete mutation homo-
plasmy. As a significant proportion of these mutations
are potentially pathogenic, these results indicate that pri-
mary dysregulation of mitochondrial function via
mtDNA mutation is a pervasive feature of cancer. They
additionally imply that higher levels of heteroplasmy or
homoplasmy (and, therefore, diminished mitochondrial
function) might be detrimental for cancer, corroborating
the importance of some key mitochondrial functions for
cancer cell survival and proliferation that are augmented
by partial mitochondrial dysfunction. This notion is sup-
ported by the finding that, in general, oncocytic tumours
harbouring mtDNA mutations at high heteroplasmy
(with significant mitochondrial dysfunction) are benign,
non-aggressive, low proliferating lesions [50, 51]. Simi-
larly, renal oncocytoma, characterised by defects in com-
plex I, exhibit clear mitochondrial and metabolic defects
that are a barrier to tumorigenesis [52, 53].
Beyond mutation alone, cancer-specific alterations in
mtDNA copy number, either specific downregulation or
upregulation [54], with similar variations at the mtRNA
level [49, 55] have also been described, potentially cor-
roborating the increased mutation abundance within
regulatory regions [49]. These data appear to support
the hypothesis that mitochondrial genetic defects and
metabolic plasticity comprise the basis for cancer-
specific metabolic rewiring strategies that encourage
tumour initiation and progression [9].
mtDNA mutations: driver, backseat driver, or
passenger?
Several lines of evidence indicate that dysregulation of
mitochondrial function plays an important role in cancer
biology, and this has been discussed in recent seminal
reviews (see for instance [8, 56]). Robust experimental
evidence for a causative, cancer-driving role of mtDNA
mutations has, however, remained elusive. Experimental
approaches to determining a role for mtDNA mutations
in cancer-associated mitochondrial dysfunction have yet
to yield conclusive data, mostly because of the genetic
intractability of the mitochondrial genome and conse-
quently limited experimental tools [57]. Despite this
major technical hurdle, compelling data exist that hint at
the nature of mtDNA-linked mitochondrial dysfunction
in cancer.
Focused clinical studies of mtDNA mutations in strati-
fied patient cohorts have been reported in the recent
past. One such report, in prostate cancer patients, dem-
onstrated a synergistic or phenotype-modifying effect (if
not true driving effect) of mtDNA mutations in the NCR
on prostate cancer aggression [58]. Further, a study of
Hürthle cell carcinoma patients revealed recurrent
homoplasmic and near-homoplasmic mutation of vari-
ous mtDNA-encoded complex I genes, associated with
widespread chromosomal loss, in nearly half of the co-
hort [52]. The mutations of mtDNA detected were
present in primary, recurrent, and metastatic tumours,
suggesting a true driver role for mtDNA mutations in
thyroid cancer. Unavoidably, however, the nature of such
clinical data, although suggestive of a role for mtDNA
mutations in cancer, cannot be used to infer their causa-
tive role.
Nuclear transfer experiments, where nuclei of cancer
cells bearing mtDNA mutations and non-cancerous
healthy cells without mtDNA mutations are exchanged,
demonstrate that a cancer cell nucleus does not trans-
form the enucleated healthy cell cytoplasm, and instead
results in an apparently healthy cell without abnormal
morphology, proliferation, or migration properties. How-
ever, transfer of the healthy nucleus into enucleated can-
cer cytoplasm, bearing mtDNA mutations, results in a
pro-metastatic transformation [59]. Many further varia-
tions of this experiment using different cell types have
produced comparable results, implicating mitochondrial
dysfunction in carcinogenesis (for a review of the field,
see [60]). A conceptually similar study, using MNX
transmitochondrial polyoma virus middle T-driven
mouse strains of breast cancer, demonstrated significant
changes in tumorigenicity and metastatic potential when
non-pathogenic mtDNAs are switched between the nu-
clear backgrounds of mouse strains [61]. Such a switch-
ing of inbred strain-specific mtDNA haplotypes between
nuclear backgrounds is likely to alter respiratory fitness
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due to co-evolution of nuclear and mitochondrial com-
ponents of the respiratory chain [62], thus crudely mim-
icking a pathogenic mtDNA. This effect was later shown
to vary, dependent upon oncogenic driver mutations,
demonstrating the potentially inconsistent impact of
mtDNA variants in cancer [63]. Overall, whilst providing
intriguing preliminary data, such experiments are sim-
plistic, easily criticised, and fail to provide mechanistic
insight.
A recent study from the authors’ laboratories more
directly addresses the question of the role of mtDNA-
linked mitochondrial dysfunction in cancer cells, using
an osteosarcoma cell line bearing the known pathogenic
mtDNA variant m.8993 T > G. This mutation leads to an
amino acid change in a key, proton-translocating subunit
of ATP synthase, resulting in mitochondrial dysfunction
at high levels of heteroplasmy [64]. Taking this initial
cell line bearing ~ 80% m.8993 T > G and using newly
developed mtDNA engineering tools, mitochondrially
targeted zinc-finger nucleases (mtZFN), to finely ma-
nipulate or ‘tune’ the heteroplasmic mutation load in a
directed manner towards wild type [65–67], it was pos-
sible to produce a collection of isogenic cancer cell lines
that varied only in mtDNA mutation load, known as
mTUNE. Analysis of mTUNE cells confirmed that mito-
chondrial dysfunction related to m.8993 T > G supports
a pro-glycolytic metabolic program that drives cell pro-
liferation and migration, phenomena that are lost when
the mutation load is reduced [68]. mTUNE additionally
enabled us to describe a new connection between
cytosolic reductive carboxylation of glutamine, a
phenomenon frequently observed in cells with mito-
chondrial dysfunction, and glycolysis, which are bio-
chemically coupled by Malate dehydrogenase 1 (MDH1)
for the supply of reducing equivalents. Such exciting
findings offer support to the emerging vision of mtDNA
mutations acting to modulate oncogenic properties of
cancer cells, causing an oncogenic or metastatic meta-
bolic switch (Fig. 4). However, substantial further data
are required to fully establish the mechanisms underpin-
ning this link.
Outlook
Metabolic dysfunction is a principal component of cancer.
From studies of primary mitochondrial disease, it is clear
that mutations of the mitochondrial genome can lead to
profound metabolic deficiency [46], and from large-scale
analysis of ICGC and TCGA datasets it is clear that
mtDNA mutations are a very common occurrence across
all solid cancers [45–47]. While recent, focused clinical
and genetic studies offer a view of mtDNA mutations as
potential drivers or phenotypic modifiers of prostate and
thyroid cancers [52, 58], robust experimental evidence in
support of a role for mtDNA mutations in cancer is
lacking.
A unified mechanism describing the role of mitochon-
drial genetic defects in cancer initiation and progression
is unlikely to be forthcoming, most probably because the
metabolic flexibility of mitochondria, and the variable
bioenergetic outcomes mtDNA mutations can produce,
Fig. 4. A model for ‘oncogenic/metastatic licensing’ through mtDNA mutation-derived mitochondrial dysfunction. Although mitochondrial
dysfunction can be advantageous to cancer cells, and possibly oncogenic to normal cells, total ablation of mitochondrial function is likely detrimental
to both. The genetic and metabolic plasticity afforded to cells bearing heteroplasmic mutations permits greater oncogenic/metastatic potential once a
threshold for heteroplasmy-induced mitochondrial dysfunction is reached. A ‘permissive metabolic zone’ of heteroplasmy-induced mitochondrial
dysfunction is proposed. Green circles, wild-type mtDNA; red circles, mutant mtDNA
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allow a range of cellular strategies for proliferation and
migration. We would tentatively propose a scenario
where cancer cells, during tumour initiation and pro-
gression, co-opt a specific degree of mitochondrial dys-
function that depends on their bioenergetic needs and
nutrient availability (Fig. 4). Beyond permitting a meta-
bolic switch that might favour anabolism, the dysregula-
tion of mitochondrial function might also provide
substrates that support (epi)genetic changes, which can
drive or fine-tune oncogenic properties. For instance,
genetic silencing or ablation of a nuclear-encoded sub-
unit of complex I in neural progenitor cells is sufficient
to cause cellular transformation through mutation of
p53 [69]. Also, the aberrant accumulation of fumarate,
2HG, or succinate due to primary or secondary mito-
chondrial dysfunction can drive epigenetic changes that
support an epithelial to mesenchymal transition [70], a
process known to drive cancer metastasis. As such,
mitochondrial dysfunction may act as a ‘metastatic li-
cense’, rather than an oncogenic one. A similar conclu-
sion could be drawn from the first robust experiments
determining the effects of mtDNA mutations in cancer
cells [68], where mitochondrial dysfunction permits
NAD+/NADH ratio changes that favour increased gly-
colysis, cell proliferation, and migration. Clinical data on
the role of mtDNA mutations in prostate cancer aggres-
sion and thyroid cancer progression would also seem to
agree with this concept [52, 58]. At the same time, how-
ever, mtDNA mutations can have a detrimental effect on
the cancer cell. For instance, severe defects in complex I
are known to diminish levels of NAD+ required by aKG
dehydrogenase, leading to an increase in the aKG:succin-
ate ratio, overactivation of prolyl hydroxylases, and the
eventual destabilisation of hypoxia inducible factors
(HIF), even at low oxygen tension, reducing tumour in-
dolence [71]. Interestingly, complex I-deficient tumours
exhibit normal angiogenesis, despite their inability to
stabilize HIFs, likely due to the contribution of cancer-
associated macrophages activated by a non-cell-
autonomous mechanism [72].
At present, mutations of mtDNA seem likely to
provide cancer cells with additional routes to tumour
initiation and progression, although profound mtDNA
mutation-induced mitochondrial dysfunction appears
detrimental (Fig. 4). Whether such a hypothesis will
persist as this young field develops remains to be
seen.
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